Skip to main content
 Home
  • Dansk
  • English

Servicemenu

  • News
  • Events
    • Previous Events
  • Themes
  • Contact
    • Contact Grants & Prizes
    • Press Contact
    • Contact The Lundbeck Foundation
    • Departments
    • Logo and Design

Hovedmenu

  • Business Activities
    • Lundbeckfonden BioCapital
      • About Lundbeckfonden BioCapital
      • Lundbeckfonden BioCapital News
      • Lundbeckfonden BioCapital Portfolio
      • Lundbeckfonden BioCapital Portfolio News
    • Strategic Investments
      • Long-Term Value Creation
      • Strategic Ownership
    • Invest
  • Grants & Prizes
    • For applicants
      • Apply for grants
      • Processing of applications
      • Review Panels
    • For grant recipients
      • Terms and Conditions - Research Grants
      • Reporting
      • Distribution of funds
    • What we have funded
      • Fellowships
      • Professorships
      • Ascending Investigators
      • Pre-Graduate Scholarships
      • LF Postdocs
      • Visiting Professorships
      • LF Experiment
      • Talentpriser
      • The Brain Prize
      • Young Investigator Prize
      • Alle
    • News - Grants & Prizes
    • Research Stories
  • Neurotorium
  • The Brain Prize
    • Overview
    • Nominations & Selection Process
    • Press and Logo
    • News
  • About Us
    • The Organisation
      • Board of Directors and Management
      • Vacancies
    • Who are we?
    • History and Statutes
    • Strategy and Purpose
      • Bringing Discoveries to Lives
    • Social Responsibility and Transparency
      • Recommendations on Foundation Governance, Corporate Governance and Transparency
      • Governance
      • Active voice in public debate
      • Policies
      • Whistleblower
    • Publikationer
      • Annual Reports
      • Sustainability Reports
      • The Magazine
      • Anniversary Book
  • Apply and Nominate

Hovedmenu - mobil

  • Business Activities
    • Lundbeckfonden BioCapital
      • About Lundbeckfonden BioCapital
      • Lundbeckfonden BioCapital News
      • Lundbeckfonden BioCapital Portfolio
      • Lundbeckfonden BioCapital Portfolio News
    • Strategic Investments
      • Long-Term Value Creation
      • Strategic Ownership
    • Invest
  • Grants & Prizes
    • For applicants
      • Apply for grants
      • Processing of applications
      • Review Panels
    • For grant recipients
      • Terms and Conditions - Research Grants
      • Reporting
      • Distribution of funds
    • What we have funded
      • Fellowships
      • Professorships
      • Ascending Investigators
      • Pre-Graduate Scholarships
      • LF Postdocs
      • Visiting Professorships
      • LF Experiment
      • Talentpriser
      • The Brain Prize
      • Young Investigator Prize
      • Alle
    • News - Grants & Prizes
    • Research Stories
  • Neurotorium
  • The Brain Prize
    • Overview
    • Nominations & Selection Process
    • Press and Logo
    • News
  • About Us
    • The Organisation
      • Board of Directors and Management
      • Vacancies
        • Personal Data Policy for Recruitment
    • Who are we?
    • History and Statutes
    • Strategy and Purpose
      • Bringing Discoveries to Lives
    • Social Responsibility and Transparency
      • Recommendations on Foundation Governance, Corporate Governance and Transparency
      • Governance
      • Active voice in public debate
      • Policies
      • Whistleblower
    • Publikationer
      • Annual Reports
      • Sustainability Reports
      • The Magazine
      • Anniversary Book
  • Apply and Nominate

Servicemenu - mobil

  • News
  • Events
    • Previous Events
  • Themes
  • Analyser
  • Contact
    • Contact Grants & Prizes
    • Press Contact
    • Contact The Lundbeck Foundation
    • Departments
    • Logo and Design
  • Dansk
  • English

Breadcrumb

  1. Home
  2. Business Activities
  3. Lundbeckfonden BioCapital
  4. Enterome

Enterome

Enterome is pioneering the development of novel microbiome based drugs to treat cancer and GI track related disorders.

Enterome's treatments are based on its proprietary Metasecretome technology, which is further divided into its OncoMimics and EndoMimics platforms. The company enables a full genomic and functional analysis of the gut microbiome and utilizes naturally occurring proteins and hormones produced by the gut bacteria for the treatment of its patients.

Related news about Enterome

  • Enterome announces first patient dosed in a Phase 1/2 trial with third OncoMimics™ immunotherapy, EO4010, in Metastatic Colorectal Cancer
  • Enterome's new OncoMimics™ immunotherapy, EO2463, demonstrates early efficacy and favorable safety in Phase 1/2 trial for indolent non-Hodgkin lymphoma
  • Enterome forms Scientific Advisory Board and Medical Advisory Group as it advances its OncoMimics™ immunotherapy pipeline for solid and liquid tumors
  • Enterome announces presentation of data from ongoing Phase 1/2 trial of its peptide-based immunotherapy EO2401 in recurrent glioblastoma (ROSALIE study) at SNO 2022
  • Enterome presents proof-of-concept immune response data and first clinical data from Phase 1/2 trial with EO2401, a first-in-class OncoMimics™ therapeutic cancer vaccine for glioblastoma, at ASCO 2022
Enterome
Enterome's website

Lundbeckfonden BioCapital

Invested
2012
Location

Paris, France

Contact

Portræt af Lars Gredsted

Lars Gredsted

Senior Principal

lgr@lundbeckfonden.com
Mobile

+45 2479 2426

Footer logo
The Lundbeck Foundation annually distributes more than DKK 500 mio. to Danish-based healthcare science research, primarily with a focus on the brain.

Lundbeckfonden
Scherfigsvej 7
2100 København Ø

CVR
11814913

Links

  • Cookie-Policy
  • Disclaimer & Privacy
  • History and Statutes
  • Our Strategy
  • Events
  • Contact
  • Jobs
Follow us
Facebook
Twitter
LinkedIn
Youtube